Hong Kong government inks deals with 22 companies, including pharmaceutical giant Pfizer, to establish or expand operations in life and health technology and other strategic sectors.

Chinese biopharma companies have driven a 132% increase in innovative drug out-licensing deals totaling $56.7 billion across 44 transactions since early 2026, underscoring China's rising dominance in the global pharmaceutical sector.

The European Economic and Social Committee has issued an opinion pushing the EU to boost biotechnology through streamlined regulations, investments, and a unified ecosystem to keep pace with global rivals.

AstraZeneca announces a $15 billion investment to enhance cell therapy, radioconjugate development, and manufacturing facilities across China, supporting oncology, haematology, and autoimmune pipelines.

The European Medicines Agency has announced an online information session on April 24, 2026, to prepare stakeholders for the upcoming breakthrough medical devices pilot launching in Q2 2026.

Chinese innovative drug outbound licensing deals exceeded RMB 400 billion in Q1 2026, with record upfront payments and focus on GLP-1, ADCs, and bispecific antibodies.

China's biopharmaceutical industry has achieved a record $56.7 billion in licensing deals, underscoring its emergence as a dominant pillar in the global pharma landscape amid heightened multinational partnerships.

China's biopharmaceutical sector achieves $56.7 billion in innovative drug out-licensing deals in early 2026, up 132% year-over-year, affirming its status as a designated emerging pillar industry.

European contract manufacturing for FDA-approved drugs surged more than threefold over the US in 2025, defying US tariffs and onshoring efforts, with Germany dominating the trend.

Biocytogen Pharmaceuticals in Beijing anticipates 46.1% annual earnings growth and 24.7% revenue rise, highlighted among Asian growth companies with high insider ownership.